Delivering on our purpose of better health for people and a brighter future for the world
Japan and Vietnam have a longstanding history of collaboration across various fields, including healthcare. Takeda Pharmaceutical Company Limited, a global pharmaceutical company, has been at the forefront of this partnership. Through joint efforts with Takeda Vietnam and Japan has made significant contributions to healthcare in Vietnam.
Latest
 |
| Dengue Conference Vietnam 2023 |
Capability Building Across Borders
One notable project is the NCGM Hereditary Angioedema (HAE) Capability Building Project, which was launched in 2021. In partnership with the National Center for Global Health and Medicines (NCGM) and the Ho Chi Minh City Society of Asthma, Allergy and Clinical Immunology (HSAACI), this initiative aims to enhance the capacity to diagnose and treat HAE in Vietnam.
Recognizing the importance of enhancing the capacity to diagnose and treat this disease, the HSAACI and Takeda signed a memorandum of understanding (MOU) in 2021, seeking support from Japan's NCGM to build knowledge and expertise in HAE diagnosis in Vietnam. Since the signing of the MOU, the NCGM HAE project has made remarkable strides in advancing HAE diagnosis and treatment. Thirty-seven seminars, conferences, and Continuing Medical Education (CME) activities have been conducted, attracting an impressive participation of 4,700 healthcare professionals - 2,025 offline and 2,675 online. The project has also assembled a network of 26 HAE experts, including six internationally renowned specialists from Japan and the USA, who generously share their knowledge and expertise as lecturers.
But perhaps the most significant achievement of the NCGM HAE project is the confirmed diagnoses of 19 individuals with HAE. This milestone represents a crucial step in their journey towards improved health and quality of life. Identifying and understanding their condition allows these individuals to access appropriate treatments and support, paving the way for a brighter future.
 |
| NCGM-HAE Capacity Building Project Review and Planning Meeting |
Partnership in Dengue Prevention and Control
In October 2023, Vietnam grappled with the number of reported cases surpassing the 100,000 mark. From January 1 to December 17, 2023, 166,619 dengue cases, including 42 fatalities, have been reported in the country. This alarming situation highlights the ongoing complexity of outbreak development in Vietnam, even in the post-pandemic era. The escalating number of cases places immense pressure on the country's healthcare infrastructure, further exacerbating Vietnam's challenges in effectively managing and combating dengue fever outbreaks.
So, in commemorating the 50th anniversary of diplomatic relations between Vietnam and Japan, Takeda, in collaboration with the Pasteur Institute in Ho Chi Minh City, organized a conference on enhancing dengue haemorrhagic fever prevention effectiveness. The conference brought together healthcare professionals from various institutions to discuss preventive initiatives and explore interventions to improve the management of dengue transmission in Vietnam. The experts from the conference alluded to the need for a sustainable and long-term solution to prevent and control dengue fever in the country.
 |
| Dengue Conference Vietnam 2023 |
Patients first by embedding an Access-First mindset in All We Do
Takeda's unwavering commitment to corporate social responsibility shines brightly through its remarkable patient support programs and initiatives. Takeda's commitment to improving access to medicines and innovative treatment solutions is exemplified through its partnership with the Ministry of Health in Vietnam. As part of their local Access to Medicines (AtM) strategy, Takeda has developed patient-centric provisions for managing rare diseases in Vietnam.
Since 2018, Takeda has been dedicated to enhancing the diagnosis and treatment of patients with haemophilia and primary immune deficiency, two prevalent rare diseases in the country. By collaborating with the Ministry of Health, Takeda aims to make a meaningful impact on the lives of patients affected by these conditions.
Meanwhile, a true pioneer in the field, Takeda launched its first Patient Assistance Program (PAP) in Vietnam in January 2023 to bridge the affordability barrier to treatment options for Hodgkin lymphoma. This rare cancer affects the lymphatic system. This PAP, the first of its kind in the country, provides tailored financial support for patients who would be otherwise unable to afford treatment.
Our Values: Takedai-sm
At the core of Takeda's values lies Takeda-ism, a unique guiding principle that serves as our compass. Through Takeda-ism, we make decisions and take action, consistently placing the patient at the centre of everything we do. Our commitment to building trust with society, reinforcing our reputation, and developing a sustainable business follows this patient-centric approach.
Takeda-ism and Patient-Trust-Reputation-Business principles form the foundation of our endeavours, shaping our actions and defining our purpose.
Tags:
